1. During the year ended March 31, 2009, the turnover of Company Increased by 29.25% and the Net Profit has increased by 28.28% over the corresponding figures of previous year.

2. The Board of Directors have recommended a Dividend of Rs.1/- per Share (10%) on Equity shares of the Company.

3. The Consolidated financial for the year ended on March 31, 2009 comprise of financial results of Ind-Swift Laboratories Ltd and Company´s wholly owned subsidiary Ind-Swift laboratories Inc., USA.

4. The Board has allotted 500000 equity shares to Other Bodies Corporates upon conversion of convertible warrants at a price of Rs.70/- per warrant.

5. The Forex Fluctuation expanses of Rs. 446.32 lacs is on account of revaluation loss incurred by company on foreign currency receivable, payable and loan as on March 31, 2009,

6. The previous period figures have been re-grouped and re-arranged wherever necessary.

7. The Company is exclusively In the Pharmaceutical business segment.

8. The above results were taken on record by the Board of Directors in its meeting held on June 29, 2009.


N R Munjal
Vice-Chairman

V K Mehta
Managing Director